About
2D Biologics is a pioneering pharmaceutical startup co-founded by Dr. Primal de Lanerolle, and David Downs, MBA. At the forefront of cancer therapeutics, the company is currently in the initial phases of developing a groundbreaking cancer drug, displaying promising results in preclinical studies for prostate cancer and breast cancer.
2D Biologics is a pioneering pharmaceutical startup co-founded by Dr. Primal de Lanerolle, and David Downs, MBA. At the forefront of cancer therapeutics, the company is currently in the initial phases of developing a groundbreaking cancer drug, displaying promising results in preclinical studies for prostate cancer and breast cancer.
Breakthrough Discovery: We have identified a drug that has no significant side effects in short-term preclinical studies and synergies with other cancer drugs to make them more effective. This approach has broad applicability and is potentially effective across most solid tumors, regardless of genetic variation. It could have a transformative impact on cancer treatment. Development Strategy: Our goal is to advance drug testing into FDA Phase 2 trials. Estimated Market Valuation: The estimated market valuation in the late stages of Phase 2: $1.7 billion.
Breakthrough Discovery: We have identified a drug that has no significant side effects in short-term preclinical studies and synergies with other cancer drugs to make them more effective. This approach has broad applicability and is potentially effective across most solid tumors, regardless of genetic variation. It could have a transformative impact on cancer treatment. Development Strategy: Our goal is to advance drug testing into FDA Phase 2 trials. Estimated Market Valuation: The estimated market valuation in the late stages of Phase 2: $1.7 billion.